This trial is active, not recruiting.

Condition severe hemophilia a
Treatment vwf/fviii concentrates
Sponsor City of Hope Medical Center
Collaborator Charta Fondazione Grant Provided by
Start date June 2009
End date June 2020
Trial size 3 participants
Trial identifier NCT01051076, 06200, 2008-007019-33


The purpose of this study is to evaluate whether a concentrate containing both FVIII and von Willebrand Factor (VWF) given at a high dose will induce immune tolerance in subjects who have already experienced and failed ITI with VWF-free FVIII concentrates. The treatment on this study is expected to last up to 33 months.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
vwf/fviii concentrates Koate-DVI
200 IU/Kg by one or two bolus injections daily. After successful confirmation the dose will be tailed off progressively until discontinuation. Patients will be treated with a VWF/FVIII concentrates according to physician/patients preference.

Primary Outcomes

Achievement of an inhibitor titer of <0.6 BU/failure to achieve an inhibitor titer of <0.6 BU within 33 months, or failure to decrease inhibitor titer by at least 20% compared to titer in prior 6 months, beginning at 3 months after starting ITI
time frame: 3 years

Secondary Outcomes

Time to achieve success- either partial or complete.
time frame: 33 months
Safety - assessment of adverse events through treatment and compliance with prolonged regimen.
time frame: 33 months
Cost of care.
time frame: Up to 45 months

Eligibility Criteria

Male participants of any age.

Inclusion Criteria: 1. severe hemophilia A (FVIII<1%) with high responding inhibitors (peak levels >5 BU) 2. male, any age; 3. any inhibitor level at study enrollment; 4. ability and willingness to participate to the study; 5. previous ITI course of at least 9 months with a VWF-free FVIII concentrate at any dosage, such as recombinant FVIII and/or monoclonally purified FVIII. Exclusion Criteria: 1. concomitant systemic treatment with immunosuppressive drugs; 2. concomitant experimental treatment; 3. previous history of myocardial infarction and/or cerebral stroke

Additional Information

Official title Immune Tolerance Induction Study in Patients With Severe Type A Haemophilia With Inhibitor After Failure of a Previous Induction of Immune Tolerance With FVII Concentrates Without Von Willebrand Factor Rescue
Principal investigator Nadia P. Ewing, MD
Description The presence of Factor VIII (FVIII) inhibitor prevents FVIII infusions from working properly and makes treatment of bleeding episodes very difficult. Having an inhibitor is a serious and life-threatening complication in patients with Hemophilia. The usual treatment of patients with FVIII inhibitors involves what is called "immune tolerance induction" (ITI). Immune Tolerance means that the body can accept infused FVIII and that FVIII is again effective in controlling bleeds. ITI involves giving high doses of FVIII regularly until the inhibitor disappears. This treatment is not always effective. The inhibitor persists in about 1 in 5 patients who undergo ITI. There are 2 types of FVIII concentrates: FVIII concentrates derived from human plasma, which contain VWF, and concentrates of FVIII without VWF. Both types of concentrates are commonly used to induce immune tolerance in patients with Hemophilia A. Retrospective studies on subjects who were treated with VWF containing Factor VIII concentrates after failing ITI with pure factor VIII concentrates, have shown that tolerance can be achieved in a large percentage of patients. This study will access prospectively whether treatment with a FVIII concentrate containing VWF given at a high dose (200 units per kilogram) daily for up to 33 months is able to induce immune tolerance after previous attempts with concentrates containing only FVIII have failed.
Trial information was received from ClinicalTrials.gov and was last updated in March 2015.
Information provided to ClinicalTrials.gov by City of Hope Medical Center.